These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 10368642)
1. 5-Fluorouracil simultaneously maintains methotrexate antineoplastic activity in human breast cancer and protects against methotrexate cytotoxicity in human bone marrow. Bowen D; Johnson DH; Southerland WM; Hughes DE; Hawkins M Anticancer Res; 1999; 19(2A):985-8. PubMed ID: 10368642 [TBL] [Abstract][Full Text] [Related]
2. Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells. Bowen D; Southerland WM; Johnson DH; Hawkins M; Hughes DE Cancer Detect Prev; 2000; 24(5):452-8. PubMed ID: 11129987 [TBL] [Abstract][Full Text] [Related]
3. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow. Das JR; Fryar-Tita EB; Zhou Y; Green S; Southerland WM; Bowen D Anticancer Res; 2007; 27(6B):3791-9. PubMed ID: 18225534 [TBL] [Abstract][Full Text] [Related]
4. Sequential combination chemotherapy in human breast cancer: a basis for increased antineoplastic activity and bone marrow protection. Davis JH; Desoto JA; Fryar EB; Southerland WM; Bowen D Cell Mol Biol (Noisy-le-grand); 2007 May; 53(3):18-26. PubMed ID: 17531145 [TBL] [Abstract][Full Text] [Related]
5. Selectivity in human breast cancer and human bone marrow using trimetrexate in combination with 5-fluorouracil. Bowen D; Johnson DH; Southerland WM; Hughes DE; Hawkins M Anticancer Res; 1999; 19(5B):3837-40. PubMed ID: 10628320 [TBL] [Abstract][Full Text] [Related]
6. Raloxifene attenuation of methotrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-FU/methotrexate. Das JR; Fryar EB; Epie NN; Southerland WM; Bowen D Anticancer Res; 2006; 26(3A):1877-83. PubMed ID: 16827120 [TBL] [Abstract][Full Text] [Related]
7. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow. Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208 [TBL] [Abstract][Full Text] [Related]
8. Sequence- and time-dependent antagonism between raloxifene and methotrexate in human breast cancer cells. De Soto JA; Bowen D; Davis JH; Southerland WM; Hawkins M Anticancer Res; 2002; 22(2A):1007-9. PubMed ID: 12014617 [TBL] [Abstract][Full Text] [Related]
9. The protection against trimetrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-fluorouracil/trimetrexate. Das JR; Fryar EB; Green S; Southerland WM; Bowen D Anticancer Res; 2006; 26(6B):4279-86. PubMed ID: 17201145 [TBL] [Abstract][Full Text] [Related]
10. Raloxifene attenuation of 5-FU/methotrexate cytotoxicity in human breast cancer cells: the importance of sequence in combination chemotherapy. Fryar EB; Das JR; Davis JH; Desoto JA; Laniyan I; Southerland WM; Bowen D Anticancer Res; 2006; 26(3A):1861-7. PubMed ID: 16827118 [TBL] [Abstract][Full Text] [Related]
11. Sequence-dependent antagonism between tamoxifen and methotrexate in human breast cancer cells. Bowen D; Southerland WM; Hawkins M; Johnson DH Anticancer Res; 2000; 20(3A):1415-7. PubMed ID: 10928050 [TBL] [Abstract][Full Text] [Related]
12. Toxicity, pathological effects, and antineoplastic activity of a non-toxic dose of 5-fluorouracil in combination with methotrexate. Robbins TJ; Bowen D Anticancer Res; 1988; 8(1):43-9. PubMed ID: 3358639 [TBL] [Abstract][Full Text] [Related]
13. Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells. Zhen YS; Taniki T; Weber G Oncol Res; 1992; 4(2):73-8. PubMed ID: 1596584 [TBL] [Abstract][Full Text] [Related]
14. Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. Koizumi S; Curt GA; Fine RL; Griffin JD; Chabner BA J Clin Invest; 1985 Mar; 75(3):1008-14. PubMed ID: 2579975 [TBL] [Abstract][Full Text] [Related]
15. [The metabolism of high-molecular-weight substances in cells and the effect of anticancer drugs]. Kanamaru R; Kakuta H; Sato T; Ishioka C; Konishi Y; Wakui A; Dei T Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):837-44. PubMed ID: 3566294 [TBL] [Abstract][Full Text] [Related]
16. Methotrexate accumulates to similar levels in animals transplanted with normal versus drug-resistant transgenic marrow. Belur LR; Boelk-Galvan D; Diers MD; McIvor RS; Zimmerman CL Cancer Res; 2001 Feb; 61(4):1522-6. PubMed ID: 11245460 [TBL] [Abstract][Full Text] [Related]
17. The interaction of the steroidal antagonist faslodex and methotrexate. DeSoto JA; Bowen D; Southerland WM; Hawkins M; Fryar EB; Davis JH Cell Mol Biol (Noisy-le-grand); 2003 Nov; 49(7):1067-9. PubMed ID: 14682388 [TBL] [Abstract][Full Text] [Related]
18. The selectivity of action of methotrexate in combination with 5-fluorouracil in xenografts of human colon adenocarcinomas. Houghton JA; Tice AJ; Houghton PJ Mol Pharmacol; 1982 Nov; 22(3):771-8. PubMed ID: 7155134 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells. Vazquez-Martin A; Ropero S; Brunet J; Colomer R; Menendez JA Oncol Rep; 2007 Oct; 18(4):973-80. PubMed ID: 17786362 [TBL] [Abstract][Full Text] [Related]
20. [Double-mutant dihydrofolate reductase gene transfection into bone marrow cells protects mice from chemotherapy]. Gao HD; Lu P; Lu Y; Pang K; Xu HM; Wang SB; Chen JQ; Zhao SC Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):583-5. PubMed ID: 17236551 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]